longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Synlogic

SYBX

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -20.94, below the reasonable range, cheaper than 86.21% of the time in the past 1 years, and the industry ranks 505/603, the industry Median -2.27.

-20.94xP/E
$1.12Stock price
$-0.05Earnings per share
-20.94xP/E
Stock price$1.12Earnings per share$-0.05

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-12.03x
Typical range
-19.46x–-4.06x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-57.04x148.77%$184.82B
MRNAUSModerna
-24.40x15.53%$76.88B
CSLLYUSCSL Limited
-23.72x--$61.19B
NTRAUSNatera
-309.73x8.22%$59.58B
RVMDUSRevolution Medicines
-24.88x63.01%$43.99B
ROIVUSRoivant Sciences
-99.21x146.49%$26.42B
INSMUSInsmed
-28.48x74.61%$24.93B
BNTXUSBioNTech SE
-12.61x17.09%$24.69B
SMMTUSSummit Therapeutics
-15.76x19.71%$13.49B
BBIOUSBridgebio Pharma
-18.59x28.48%$12.86B
TWSTUSTwist Bioscience
-93.05x20.00%$12.72B
MDGLUSMadrigal Pharma
-35.82x51.06%$11.64B
IBRXUSImmunityBio
-10.08x152.63%$10.00B
KYMRUSKymera Therapeutics
-31.03x4.94%$9.30B
ARWRUSArrowHead Pharma
-28.90x36,308.30%$9.25B
CYTKUSCytokinetics
-10.25x6.37%$9.16B
ABVXUSAbivax SA
-18.53x22.49%$8.63B
PCVXUSVaxcyte
-7.96x48.80%$8.47B
PRAXUSPraxis Precision Medicines
-23.98x3.05%$8.13B
SYREUSSpyre Therapeutics
-52.26x46.89%$7.85B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.